Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ANHYDROUS DOCETAXEL CRS (15 MG)

ANHYDROUS DOCETAXEL CRS (15 MG)

114977-28-5

DISCOVER
AMIKACIN IMPURITY I CRS (20 MG)

AMIKACIN IMPURITY I CRS (20 MG)

40371-51-5

DISCOVER
SODIUM IODOHIPPURATE CRS (15 MG)

SODIUM IODOHIPPURATE CRS (15 MG)

5990-94-3

DISCOVER
SULFADIAZINE IMPURITY A CRS (20 MG)

SULFADIAZINE IMPURITY A CRS (20 MG)

109-12-6

DISCOVER
BENZOIC ACID CRS (30 MG)

BENZOIC ACID CRS (30 MG)

65-85-0

DISCOVER
APOMORPHINE IMPURITY B CRS - * NARC (MORPHINE HEMISULFATE PE

APOMORPHINE IMPURITY B CRS - * NARC (MORPHINE HEMISULFATE PE

6211-15-0

DISCOVER
COAGULATION FACTORS  V, VIII,XI AND XIII PLASMA BRP (1 MG)

COAGULATION FACTORS V, VIII,XI AND XIII PLASMA BRP (1 MG)

NA

DISCOVER
GOSERELIN FOR NMR IDENTIFICATION CRS (14 MG)

GOSERELIN FOR NMR IDENTIFICATION CRS (14 MG)

65807-02-5

DISCOVER
LAURIC ACID CRS (1500 MG)

LAURIC ACID CRS (1500 MG)

143-07-7

DISCOVER
PIROXICAM FOR SYSTEM SUITABILITY CRS (15 MG)

PIROXICAM FOR SYSTEM SUITABILITY CRS (15 MG)

36322-90-4

DISCOVER
PIPEMIDIC ACID TRIHYDRATE CRS(15 MG)

PIPEMIDIC ACID TRIHYDRATE CRS(15 MG)

72571-82-5

DISCOVER
DEXAMETHASONE SODIUM PHOSPHATE FOR PEAK IDENTIFICATION CRS (

DEXAMETHASONE SODIUM PHOSPHATE FOR PEAK IDENTIFICATION CRS (

2392-39-4

DISCOVER